Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IMGN853

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Grade 3 endometrioid and uterine serous carcinomas (USC) account for the vast majority of endometrial cancer deaths. The purpose… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2017
Highly Cited
2017
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an… Expand
2017
2017
Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα). In this phase… Expand
2017
2017
5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-binding… Expand
2017
2017
5553Background: FORWARD II is a phase 1b study of the FRα-targeting ADC, mirvetuximab soravtansine (IMGN853), in combination with… Expand
2016
2016
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2015
Highly Cited
2015
A majority of ovarian and non–small cell lung adenocarcinoma cancers overexpress folate receptor α (FRα). Here, we report the… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2015
2015
5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-binding antibody conjugated with… Expand
2014
2014
5571 Background: IMGN853 is a FRα-targeting ADC that comprises a FRa-binding antibody conjugated with the potent maytansinoid… Expand
2013
2013
2573 Background: IMGN853 is an antibody-drug conjugate (ADC) comprising a folate receptor 1 (FOLR1)-binding antibody and the… Expand